MD3377485T2 - Formă în stare solidă a unor compuși de piridină pladienolidă și metode de utilizare - Google Patents
Formă în stare solidă a unor compuși de piridină pladienolidă și metode de utilizareInfo
- Publication number
- MD3377485T2 MD3377485T2 MDE20180923T MDE20180923T MD3377485T2 MD 3377485 T2 MD3377485 T2 MD 3377485T2 MD E20180923 T MDE20180923 T MD E20180923T MD E20180923 T MDE20180923 T MD E20180923T MD 3377485 T2 MD3377485 T2 MD 3377485T2
- Authority
- MD
- Moldova
- Prior art keywords
- solid state
- state form
- methods
- pladienolide
- pyridine compounds
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 150000003222 pyridines Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Prezenta descriere prevede o nouă formă solidă a compuşilor de piridină pladienolidă, compoziţii cuprinzând cel puţin o astfel de formă de stare solidă şi metode de preparare şi utilizare a acestora. Noua formă în stare solidă a compuşilor de piridină pladienolidă poate fi utilă în tratamentul cancerului, cum ar fi, de exemplu, cancerele în care sunt cunoscuţi ca fiind utili, agenţii care vizează spliceozomul şi mutaţiile din acesta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257088P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062525 WO2017087667A1 (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3377485T2 true MD3377485T2 (ro) | 2020-02-29 |
Family
ID=57472076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20180923T MD3377485T2 (ro) | 2015-11-18 | 2016-11-17 | Formă în stare solidă a unor compuși de piridină pladienolidă și metode de utilizare |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10745387B2 (ro) |
| EP (1) | EP3377485B1 (ro) |
| JP (2) | JP6312282B2 (ro) |
| KR (1) | KR20180083376A (ro) |
| CN (1) | CN108473479B (ro) |
| AU (2) | AU2016357433B2 (ro) |
| BR (1) | BR112018009995B1 (ro) |
| CA (1) | CA3004623C (ro) |
| ES (1) | ES2757174T3 (ro) |
| IL (1) | IL259198B2 (ro) |
| MD (1) | MD3377485T2 (ro) |
| MX (2) | MX2018006155A (ro) |
| RU (2) | RU2021102393A (ro) |
| SG (2) | SG11201803519YA (ro) |
| WO (1) | WO2017087667A1 (ro) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020010606A (es) * | 2018-04-09 | 2021-01-15 | Eisai R&D Man Co Ltd | Compuestos de pladienolida y su uso. |
| SG11202009907XA (en) | 2018-04-12 | 2020-11-27 | Eisai R&D Man Co Ltd | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
| US20210346371A1 (en) * | 2018-06-01 | 2021-11-11 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
| WO2021113773A2 (en) * | 2019-12-04 | 2021-06-10 | Pai Athma A | Identifying non-productive splice sites |
| EP4240360A1 (en) | 2020-11-04 | 2023-09-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| AU2003252299A1 (en) | 2002-07-31 | 2004-02-16 | Eisai Co., Ltd. | Novel physiologically active substance |
| WO2004011661A1 (ja) | 2002-07-31 | 2004-02-05 | Mercian Corporation | 新規生理活性物質 |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| US7745198B2 (en) | 2002-11-29 | 2010-06-29 | Mercian Corporation | Method of producing macrolide compound |
| CA2546614A1 (en) | 2003-11-27 | 2005-06-09 | Mercian Corporation | Dna participating in hydroxylation of macrolide compound |
| CA2552553C (en) | 2003-11-28 | 2015-01-06 | Kanagawa Academy Of Science And Technology | Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer |
| EP1764592A4 (en) | 2004-07-02 | 2009-08-19 | Plus One Techno & Co Ltd | COMBINED WEIGHING APPARATUS |
| EP1770165B1 (en) | 2004-07-20 | 2011-12-21 | Eisai R&D Management Co., Ltd. | Dna coding for polypeptide participating in biosynthesis of pladienolide |
| TW200716744A (en) | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| EP1935893A4 (en) | 2005-10-13 | 2009-07-22 | Eisai R&D Man Co Ltd | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D |
| US20100021918A1 (en) * | 2007-03-05 | 2010-01-28 | Eisai R&D Management Co., Ltd. | Method for assaying action of antitumor agent using splicing defects as index |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| KR101710318B1 (ko) | 2014-05-15 | 2017-02-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 플라디에놀리드 피리딘 화합물 및 사용 방법 |
-
2016
- 2016-11-17 IL IL259198A patent/IL259198B2/en unknown
- 2016-11-17 ES ES16805664T patent/ES2757174T3/es active Active
- 2016-11-17 RU RU2021102393A patent/RU2021102393A/ru unknown
- 2016-11-17 KR KR1020187016598A patent/KR20180083376A/ko not_active Application Discontinuation
- 2016-11-17 US US15/529,798 patent/US10745387B2/en active Active
- 2016-11-17 MX MX2018006155A patent/MX2018006155A/es unknown
- 2016-11-17 RU RU2018121610A patent/RU2743349C2/ru active
- 2016-11-17 MD MDE20180923T patent/MD3377485T2/ro unknown
- 2016-11-17 EP EP16805664.6A patent/EP3377485B1/en active Active
- 2016-11-17 CN CN201680067749.5A patent/CN108473479B/zh active Active
- 2016-11-17 SG SG11201803519YA patent/SG11201803519YA/en unknown
- 2016-11-17 MX MX2021001441A patent/MX2021001441A/es unknown
- 2016-11-17 WO PCT/US2016/062525 patent/WO2017087667A1/en active Application Filing
- 2016-11-17 JP JP2017528992A patent/JP6312282B2/ja active Active
- 2016-11-17 AU AU2016357433A patent/AU2016357433B2/en active Active
- 2016-11-17 CA CA3004623A patent/CA3004623C/en active Active
- 2016-11-17 SG SG10201913045PA patent/SG10201913045PA/en unknown
- 2016-11-17 BR BR112018009995-3A patent/BR112018009995B1/pt active IP Right Grant
-
2018
- 2018-03-16 JP JP2018049098A patent/JP6353620B1/ja active Active
-
2020
- 2020-07-17 US US16/932,627 patent/US20200361915A1/en not_active Abandoned
-
2021
- 2021-02-15 AU AU2021200974A patent/AU2021200974B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3316969T2 (ro) | Compuși antibacterieni | |
| MD3377485T2 (ro) | Formă în stare solidă a unor compuși de piridină pladienolidă și metode de utilizare | |
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| WO2018112365A3 (en) | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| EA201990043A1 (ru) | Антибактериальные соединения | |
| MX2017004579A (es) | Estructuras fibrosas solubles y metodos para fabricarlas. | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| MX2018001324A (es) | Forma cristalina de base libre de lorlatinib. | |
| EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| EA033460B1 (ru) | Замещенные [1,2,4]триазольные соединения в качестве фунгицидов | |
| GEP201706760B (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same | |
| TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
| NO20180002A1 (en) | Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors | |
| MX2021008225A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
| WO2014147504A3 (en) | Process for preparation of 2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms | |
| MX360040B (es) | Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno. | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs | |
| IN2013CH05858A (ro) |